jump to content jump to footer

Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer

In a retrospective study conducted at the University Hospital Cologne, the radiological criteria iRECIST and RECIST 1.1 were compared for assessing treatment response in melanoma and NSCLC patients receiving immune checkpoint inhibitors.

The results indicate that iRECIST is better suited for capturing atypical treatment responses to immunotherapies, especially in patients experiencing pseudoprogression. iRECIST could thus contribute to a more accurate evaluation of treatment response and improved immunotherapy outcomes.

Read more about the study here.

Research with mint mintLesion Clinical Research Standardized Reading Procedures iRECIST RECIST

Related Resources

From PCWG3 to PCWG4: Evolving Standards in Prostate Cancer Clinical Trials

The Prostate Cancer Working Group 4 (PCWG4) updates and extends the recommendations of PCWG3 to reflect a patient-centric approach, the emergence of…

Mint Medical and mediaire strengthen the prostate cancer care pathway with AI-Powered MRI Solutions

Mint Medical, a Snke company, and mediaire announce a collaboration to advance AI‑powered MRI workflows through the interoperability of mint Lesion…

Medical professional reviewing patient's MRI images on computer monitor with patient in MRI machine in background.
TGSE-BLADE demonstrated significantly reduced geometric distortion and artifacts caused by intracranial air, enabling more accurate detection of ischemic changes and improving diagnostic confidence in early postoperative MRI.
Postoperative Brain MRI After Tumor Resection: Reducing Artifacts and Improving Diagnostic Accuracy

Postoperative MRI after brain tumor surgery is often affected by artifacts caused by intracranial air, limiting reliable image interpretation.

A…